Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nrx Pharmaceuticals Inc (NRXP)

Nrx Pharmaceuticals Inc (NRXP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 84,323
  • Shares Outstanding, K 33,068
  • Annual Sales, $ 1,230 K
  • Annual Income, $ -28,620 K
  • EBIT $ -16 M
  • EBITDA $ -16 M
  • 60-Month Beta 1.83
  • Price/Sales 67.76
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 117.58% (-68.29%)
  • Historical Volatility 87.73%
  • IV Percentile 5%
  • IV Rank 14.13%
  • IV High 734.57% on 02/13/26
  • IV Low 16.06% on 09/08/25
  • Expected Move (DTE 27) 0.37 (14.33%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2,198
  • Volume Avg (30-Day) 435
  • Put/Call OI Ratio 0.33
  • Today's Open Interest 7,283
  • Open Int (30-Day) 5,791
  • Expected Range 2.18 to 2.92

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $0.00
  • Number of Estimates 2
  • High Estimate $0.01
  • Low Estimate $-0.02
  • Prior Year $-0.34
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.72 +48.26%
on 03/23/26
2.61 -2.30%
on 04/16/26
+0.60 (+30.77%)
since 03/17/26
3-Month
1.62 +57.41%
on 03/09/26
2.61 -2.30%
on 04/16/26
+0.28 (+12.33%)
since 01/16/26
52-Week
1.62 +57.41%
on 03/09/26
3.84 -33.59%
on 10/07/25
+0.62 (+32.12%)
since 04/17/25

Most Recent Stories

More News
NRx Pharmaceuticals (NASDAQ: NRXP) Forms NRx Defense Systems Subsidiary to Advance Neuroplastic Therapies for Military and Government Applications

NRx Pharmaceuticals (NASDAQ: NRXP), a biopharmaceutical company focused on neuroplastic therapies for depression and PTSD, announced the formation of NRx Defense Systems Inc., a Florida-based research...

NRXP : 2.55 (+1.59%)
NRx Pharmaceuticals Advances Robotic-Enabled Transcranial Magnetic Stimulation Combined with Neuroplastic Therapy for Military and First Responder Applications

Dr. Dennis K. McBride, PhD (CAPT, Medical Service Corps, US Navy, Ret., Distinguished Research Fellow, National Defense University, and former senior executive, Office Secretary of Defense) to serve as...

NRXP : 2.55 (+1.59%)
NRx Pharmaceuticals (NASDAQ: NRXP) Appoints First Chief Commercial Officer Ahead of Ketamine Launch

NRx Pharmaceuticals (NASDAQ: NRXP), a biopharmaceutical company focused on neuroplastic therapies for depression, PTSD and related conditions, announced the appointment of Glenn Tyson as its first Chief...

NRXP : 2.55 (+1.59%)
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Appointment of Glenn Tyson as the Company’s first Chief Commercial Officer

Mr Tyson has both clinical experience treating patients with serious mental health disorders and 25 years of successful industry commercial experience in the development and sales of medications in this...

NRXP : 2.55 (+1.59%)
NRx Pharmaceuticals (NASDAQ: NRXP) Receives FDA Labeling Feedback for Preservative-Free Ketamine Application

NRx Pharmaceuticals (NASDAQ: NRXP) announced it has received a letter from the FDA Office of Generic Drugs indicating only minor formatting comments on the proposed label for its preservative-free ketamine...

NRXP : 2.55 (+1.59%)
NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Labeling Alignment for NRx’s Preservative-Free Ketamine Application

NRx has received a letter from the FDA Office of Generic Drugs indicating preliminary alignment on labeling for NRx’s preservative-free ketamine product. Labeling remains subject to final supervisory...

NRXP : 2.55 (+1.59%)
Hope Therapeutics, an NRx Pharmaceuticals Subsidiary (Nasdaq:NRXP), Announces Strategic Partnership with Emobot to Integrate its AI-Powered “Depression Thermometer” Across its Interventional Psychiatry Network

Hope Therapeutics (subsidiary of NRx Pharmaceuticals, Nasdaq: NRXP) partners with Emobot Health to deploy its AI-powered "Depression Thermometer" across its interventional psychiatry clinic network. Emobot's...

NRXP : 2.55 (+1.59%)
New to The Street Broadcasts Show #740 on Bloomberg Television at 6:30 PM EST Featuring Medicus (MDCX), Acme Markets- Canton Foundation, Alpha Ton Capital (ATON), and Virtuix Holdings (NASDAQ:VTIX)

The show also broadcasts across MENA and Latin America as sponsored programming.

TRN : 32.95 (+1.48%)
PETV : 0.7990 (unch)
SNYR : 0.5246 (+3.49%)
ACXP : 2.38 (-4.42%)
IGC : 0.3359 (+4.64%)
VTIX : 6.17 (+1.31%)
LTRN : 2.49 (-1.97%)
NRXP : 2.55 (+1.59%)
YYGH : 1.6100 (+5.92%)
DVLT : 0.7580 (-9.49%)
VVOS : 0.9741 (-10.63%)
NRx Pharmaceuticals (NASDAQ: NRXP) Files 2025 Form 10-K And Highlights Operational Progress

NRx Pharmaceuticals (NASDAQ: NRXP) announced the filing of its Form 10-K for the year ended Dec. 31, 2025, highlighting progress across its clinical-stage pipeline and HOPE Therapeutics operations, including...

NRXP : 2.55 (+1.59%)
NRx Pharmaceuticals (Nasdaq:NRXP) Reports Full-Year 2025 Results and Highlights Key Regulatory and Commercial Progress

Key highlights for the first full year of operation under the new management team include: A year-over-year reduction in operating expenses with $7.8 Million cash on hand at year end. With ongoing...

NRXP : 2.55 (+1.59%)

Business Summary

NRX Pharmaceuticals Inc. is a patient-focused, clinical stage pharmaceutical company. It creates therapies to treat diseases where no medicines currently exist. NRX Pharmaceuticals Inc., formerly known as Big Rock Partners Acquisition Corp., is based in RADNOR, Pa.

See More

Key Turning Points

3rd Resistance Point 2.67
2nd Resistance Point 2.62
1st Resistance Point 2.59
Last Price 2.55
1st Support Level 2.50
2nd Support Level 2.45
3rd Support Level 2.42

See More

52-Week High 3.84
Fibonacci 61.8% 2.99
Fibonacci 50% 2.73
Last Price 2.55
Fibonacci 38.2% 2.47
52-Week Low 1.62

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.